RT Journal Article
SR Electronic
A1 Vinall, Phil
T1 Impact of LX4211 on Cardiovascular Risk Factors in Type 2 Diabetes
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 18
SP 26
OP 27
DO 10.1177/155989771218017
UL http://mdc.sagepub.com/content/12/18/26.abstract
AB LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1/2), demonstrated a clear dose reduction in plasma glucose concentration (HbA1C) in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin monotherapy in the Safety and Efficacy of LX4211 with Metformin in T2DM Patients with Inadequate Glycemic Control on Metformin study. SGLT1 is primarily responsible for gastrointestinal glucose absorption, while SGLT2 is primarily responsible for renal glucose reabsorption, leading to reductions in blood glucose levels and weight loss.